Literature DB >> 26554698

Can Acute Kidney Injury Be Considered a Clinical Quality Measure.

Matthew T James1, Neesh Pannu.   

Abstract

Quality indicators are measurements of healthcare outcome, process, or structure that can be used as tools to measure the quality of care and identify opportunities for improvement. Acute kidney injury (AKI) has many characteristics that make it a potential target for quality indicator development. It is common, associated with a high risk of adverse outcomes, and there are reports of gaps in the quality of care in several clinical settings despite publication of evidence-based guidelines. Substantial work has already been undertaken to develop quality measures related to AKI following percutaneous coronary interventions and major surgical procedures. This paper reviews the current literature that has addressed issues of prevention or management of AKI as outcome, process, or structure quality indicators in these clinical settings. Several current controversies about the appropriateness of such indicators related to AKI are identified. Further research to strengthen the evidence-base supporting prevention and management initiatives for AKI across all relevant clinical settings is needed to clarify the role of AKI as a target for clinical quality indicators.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 26554698     DOI: 10.1159/000441426

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  2 in total

1.  Statin use and the risk of acute kidney injury in older adults.

Authors:  Marcello Tonelli; Anita M Lloyd; Aminu K Bello; Matthew T James; Scott W Klarenbach; Finlay A McAlister; Braden J Manns; Ross T Tsuyuki; Brenda R Hemmelgarn
Journal:  BMC Nephrol       Date:  2019-03-25       Impact factor: 2.388

2.  Quality Improvement Goals for Acute Kidney Injury.

Authors:  Kianoush Kashani; Mitchell Howard Rosner; Michael Haase; Andrew J P Lewington; Donal J O'Donoghue; F Perry Wilson; Mitra K Nadim; Samuel A Silver; Alexander Zarbock; Marlies Ostermann; Ravindra L Mehta; Sandra L Kane-Gill; Xiaoqiang Ding; Peter Pickkers; Azra Bihorac; Edward D Siew; Erin F Barreto; Etienne Macedo; John A Kellum; Paul M Palevsky; Ashita Jiwat Tolwani; Claudio Ronco; Luis A Juncos; Oleksa G Rewa; Sean M Bagshaw; Theresa Ann Mottes; Jay L Koyner; Kathleen D Liu; Lui G Forni; Michael Heung; Vin-Cent Wu
Journal:  Clin J Am Soc Nephrol       Date:  2019-05-17       Impact factor: 8.237

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.